Hoffman-LaRoche Inc said Eli Lilly andCo Inc will pay it royalties on the sale of Lilly's humangrowth hormone, Humatrope, as part of an earlier-reportedlicensing agreement between the companies.    Hoffman-La Roche spokesman John Doorley declined todisclose the amount of the royalty payments.    "Lilly has taken the position of respecting our patent bypaying us roylaties," said Doorley. "We are hopeful that othercompanies will respect that position," he said.    Roche is the licensee of a Hormone Research Foundationpatent for a synthetic version of human growth hormone.       Last September, Roche and the Foundation sued Genetech Inc&lt;GENE> alleging Genetech's product, Protropin, a human growthhormone, infringed on Hoffman's patent for the hormone.    Last year Genetech's sales of Protropin were about 35 mlndlrs. David Saks, drug analyst with Morgan Olmstead, Kennedyand Gardner in New York, said Genetech's and Lilly's productcan each bring in about 50 mln dlrs in sales annually.    Other companies developing human growth hormone includeBiotechnology General Corp. Roche's Doorley said the companyhad at one time started developing a growth hormone but decidedto put its efforts into other products. Reuter&#3;